Summary
5.82 -0.23(-3.73%)05/20/2024
Angiodynamic Inc (ANGO)
Angiodynamic Inc (ANGO)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.97 | 6.04 | -7.11 | 0.99 | -6.97 | -31.47 | -69.75 | -50.88 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 6.14 | |
| Open | 6.24 | |
| High | 6.26 | |
| Low | 6.12 | |
| Volume | 278,878 | |
| Change | -0.06 | |
| Change % | -0.97 | |
| Avg Volume (20 Days) | 441,478 | |
| Volume/Avg Volume (20 Days) Ratio | 0.63 | |
| 52 Week Range | 5.26 - 11.38 | |
| Price vs 52 Week High | -46.05% | |
| Price vs 52 Week Low | 16.73% | |
| Range | -1.60 | |
| Gap Up/Down | -0.16 | |
Fundamentals | ||
| Market Capitalization (Mln) | 233 | |
| EBIDTA | -4,915,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 1.8700 | |
| WallStreet Target Price | 13.50 | |
| Book Value | 5.4100 | |
| Earnings Per Share | -4.8000 | |
| EPS Estimate Current Quarter | -0.1300 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | -0.5200 | |
| EPS Estimate Next Year | -0.4900 | |
| Diluted EPS (TTM) | -4.8000 | |
| Revenues | ||
| Profit Marging | -0.5937 | |
| Operating Marging (TTM) | -0.1928 | |
| Return on asset (TTM) | -0.0481 | |
| Return on equity (TTM) | -0.6242 | |
| Revenue TTM | 324,008,000 | |
| Revenue per share TTM | 8.1050 | |
| Quarterly Revenue Growth (YOY) | -0.0690 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 174,246,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 96.1538 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.1667 | |
| Revenue Enterprise Value | 0.6243 | |
| EBITDA Enterprise Value | -5.7680 | |
| Shares | ||
| Shares Outstanding | 40,054,500 | |
| Shares Float | 38,887,744 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.07 | |
| Insider (%) | 5.00 | |
| Institutions (%) | 88.93 | |
05/06 16:45 EST - businesswire.com
AngioDynamics' APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that results from the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV) were presented at The Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions hos.
AngioDynamics' APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that results from the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV) were presented at The Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions hos.
04/09 16:49 EST - seekingalpha.com
A Leaner AngioDynamics Is A High-Risk Execution-Driven Story
AngioDynamics has sold low-growth businesses, shifted to an outsourced manufacturing model, and refocused on cardiovascular and oncological care for potential growth. The recent approval of the AlphaVac F18 mechanical thrombectomy system for pulmonary embolism presents a significant opportunity in a large ($2B+) and growing market. The company's historical execution challenges raise concerns, but there is potential for a stronger, more profitable AngioDynamics if products like Auryon, AlphaVac, and NanoKnife are successful.
A Leaner AngioDynamics Is A High-Risk Execution-Driven Story
AngioDynamics has sold low-growth businesses, shifted to an outsourced manufacturing model, and refocused on cardiovascular and oncological care for potential growth. The recent approval of the AlphaVac F18 mechanical thrombectomy system for pulmonary embolism presents a significant opportunity in a large ($2B+) and growing market. The company's historical execution challenges raise concerns, but there is potential for a stronger, more profitable AngioDynamics if products like Auryon, AlphaVac, and NanoKnife are successful.
04/05 12:56 EST - zacks.com
AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates
Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.
AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates
Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.
04/05 12:46 EST - zacks.com
AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment
AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment
AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
04/04 11:11 EST - seekingalpha.com
AngioDynamics (ANGO) Q3 2024 Earnings Call Transcript
AngioDynamics Inc. (NASDAQ:ANGO ) Q3 2024 Earnings Conference Call April 4, 2024 8:00 AM ET Company Participants Jim Clemmer - President, Chief Executive Officer Steve Trowbridge - Executive Vice President, Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James Steve Lichtman - Oppenheimer & Co. John Young - Canaccord Genuity Operator Good morning and welcome to the AngioDynamics fiscal year 2024 third quarter earnings call. At this time, all participants are in a listen-only mode.
AngioDynamics (ANGO) Q3 2024 Earnings Call Transcript
AngioDynamics Inc. (NASDAQ:ANGO ) Q3 2024 Earnings Conference Call April 4, 2024 8:00 AM ET Company Participants Jim Clemmer - President, Chief Executive Officer Steve Trowbridge - Executive Vice President, Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James Steve Lichtman - Oppenheimer & Co. John Young - Canaccord Genuity Operator Good morning and welcome to the AngioDynamics fiscal year 2024 third quarter earnings call. At this time, all participants are in a listen-only mode.
04/04 07:00 EST - businesswire.com
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO): Fiscal Year 2024 Third Quarter Highlights Completed the sale of its PICC and Midline product portfolios to Spectrum Vascular on February 15, 2024 Discontinued its Uniblate and Starburst RadioFrequency products, as well as its Syntrax support catheter products, to further streamline its product portfolio GAAP As Reported Pro Forma* Net Sales: $75.2 million $66.0 million Growth: N/A 8.0% Gross Margin 47.7% 51.1% GAAP Loss per Sh.
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO): Fiscal Year 2024 Third Quarter Highlights Completed the sale of its PICC and Midline product portfolios to Spectrum Vascular on February 15, 2024 Discontinued its Uniblate and Starburst RadioFrequency products, as well as its Syntrax support catheter products, to further streamline its product portfolio GAAP As Reported Pro Forma* Net Sales: $75.2 million $66.0 million Growth: N/A 8.0% Gross Margin 47.7% 51.1% GAAP Loss per Sh.
04/04 06:45 EST - businesswire.com
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the United States Food and Drug Administration (FDA) has cleared the AlphaVac F1885 System for the treatment of pulmonary embolism (PE), enhancing its utility in critical medical scenarios such as PE. PE affect.
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the United States Food and Drug Administration (FDA) has cleared the AlphaVac F1885 System for the treatment of pulmonary embolism (PE), enhancing its utility in critical medical scenarios such as PE. PE affect.
04/02 11:36 EST - zacks.com
AngioDynamics (ANGO) Settles Patent Litigations With BD
AngioDynamics (ANGO) announces its settlement agreement with BD's affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.
AngioDynamics (ANGO) Settles Patent Litigations With BD
AngioDynamics (ANGO) announces its settlement agreement with BD's affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.
04/01 17:26 EST - businesswire.com
AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it has entered into a settlement agreement with Becton, Dickinson and Company (“BD”) to resolve all outstanding patent litigation with C.R. Bard, Inc., an affiliate of BD. Under the terms of the settlement, BD.
AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it has entered into a settlement agreement with Becton, Dickinson and Company (“BD”) to resolve all outstanding patent litigation with C.R. Bard, Inc., an affiliate of BD. Under the terms of the settlement, BD.
03/28 11:00 EST - zacks.com
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
03/19 16:01 EST - businesswire.com
AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market open on Thursday, April 4, 2024. The Company's management will host a conference call at 8:00 a.m. ET the same day to.
AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market open on Thursday, April 4, 2024. The Company's management will host a conference call at 8:00 a.m. ET the same day to.
03/15 19:21 EST - zacks.com
AngioDynamics (ANGO) Declines More Than Market: Some Information for Investors
In the most recent trading session, AngioDynamics (ANGO) closed at $5.37, indicating a -0.74% shift from the previous trading day.
AngioDynamics (ANGO) Declines More Than Market: Some Information for Investors
In the most recent trading session, AngioDynamics (ANGO) closed at $5.37, indicating a -0.74% shift from the previous trading day.
03/08 19:16 EST - zacks.com
Why AngioDynamics (ANGO) Dipped More Than Broader Market Today
In the most recent trading session, AngioDynamics (ANGO) closed at $5.67, indicating a -1.39% shift from the previous trading day.
Why AngioDynamics (ANGO) Dipped More Than Broader Market Today
In the most recent trading session, AngioDynamics (ANGO) closed at $5.67, indicating a -1.39% shift from the previous trading day.
03/06 16:01 EST - businesswire.com
AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 34th Annual Virtual Healt.
AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 34th Annual Virtual Healt.
03/04 18:42 EST - investorplace.com
Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound
Ordinarily, you'll want to avoid excessively red-stained ideas. Although certain exceptions might be made for these oversold stocks ready for rebound.
Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound
Ordinarily, you'll want to avoid excessively red-stained ideas. Although certain exceptions might be made for these oversold stocks ready for rebound.
02/22 19:15 EST - zacks.com
Here's Why AngioDynamics (ANGO) Gained But Lagged the Market Today
In the most recent trading session, AngioDynamics (ANGO) closed at $5.99, indicating a +1.7% shift from the previous trading day.
Here's Why AngioDynamics (ANGO) Gained But Lagged the Market Today
In the most recent trading session, AngioDynamics (ANGO) closed at $5.99, indicating a +1.7% shift from the previous trading day.
02/16 12:01 EST - zacks.com
AngioDynamics (ANGO) Divests Its PICC & Midline Businesses
AngioDynamics (ANGO) finalizes its PICC and Midline businesses divestment to Spectrum Vascular to optimize its product portfolio and to focus on strengthening its med tech segment.
AngioDynamics (ANGO) Divests Its PICC & Midline Businesses
AngioDynamics (ANGO) finalizes its PICC and Midline businesses divestment to Spectrum Vascular to optimize its product portfolio and to focus on strengthening its med tech segment.
02/15 19:16 EST - zacks.com
Why AngioDynamics (ANGO) Outpaced the Stock Market Today
AngioDynamics (ANGO) closed at $6.17 in the latest trading session, marking a +1.31% move from the prior day.
Why AngioDynamics (ANGO) Outpaced the Stock Market Today
AngioDynamics (ANGO) closed at $6.17 in the latest trading session, marking a +1.31% move from the prior day.
02/09 19:16 EST - zacks.com
AngioDynamics (ANGO) Stock Sinks As Market Gains: Here's Why
The latest trading day saw AngioDynamics (ANGO) settling at $6.09, representing a -0.98% change from its previous close.
AngioDynamics (ANGO) Stock Sinks As Market Gains: Here's Why
The latest trading day saw AngioDynamics (ANGO) settling at $6.09, representing a -0.98% change from its previous close.
01/25 11:36 EST - zacks.com
AngioDynamics' (ANGO) New XL Catheter to Help in PAD Treatment
AngioDymics' (ANGO) new FDA-approved Auryon XL Catheter is likely to boost PAD treatment by eliminating access site complications in Atherectomy procedures.
AngioDynamics' (ANGO) New XL Catheter to Help in PAD Treatment
AngioDymics' (ANGO) new FDA-approved Auryon XL Catheter is likely to boost PAD treatment by eliminating access site complications in Atherectomy procedures.